<DOC>
	<DOCNO>NCT01498289</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , oxaliplatin , leucovorin calcium , fluorouracil , irinotecan hydrochloride , docetaxel , work different way stop growth tumor cell , either kill cell stop dividing . Combining one drug may kill tumor cell . It yet know regimen combination chemotherapy effective treat tumor cell . PURPOSE : This randomized phase II trial study well oxaliplatin , leucovorin calcium , fluorouracil work compare irinotecan hydrochloride docetaxel treat patient esophageal cancer , gastric cancer , gastroesophageal junction cancer .</brief_summary>
	<brief_title>S1201 : Combination Chemo Patients W/Advanced Metastatic Esophageal , Gastric , Gastroesophageal Junction Cancer</brief_title>
	<detailed_description>OBJECTIVES : - To assess progression-free survival high-excision repair cross-complementing 1 ( ERCC1 ) patient advanced metastatic cancer esophagus , stomach , gastroesophageal junction ( GEJ ) treat FOLFOX comprise oxaliplatin , leucovorin calcium , fluorouracil compare treated irinotecan hydrochloride plus docetaxel . - To assess progression-free survival low-ERCC1 patient advanced metastatic cancer esophagus , stomach , GEJ treat FOLFOX compare treat irinotecan hydrochloride plus docetaxel . - To assess progression-free survival low-ERCC1 patient advanced metastatic cancer esophagus , stomach , GEJ treat FOLFOX compare high-ERCC1 patient treat FOLFOX . - To assess overall survival toxicity two treatment arm group patient . - To assess response probability ( confirm unconfirmed , complete partial response ) subset patient measurable disease two treatment arm . - To explore whether evidence interaction treatment arm ERCC1 expression group patient . ( Exploratory ) - To bank tissue blood future translational medicine study ; ) To explore relationship ERCC-1 ERCC-2 single nucleotide polymorphism ( SNP ) genotypes clinical outcome patient ; b ) To explore association germline variation SNPs ERCC-1 mRNA expression patient . ( Exploratory ) OUTLINE : This multicenter study . Patients stratify accord ERCC1 expression ( high [ ≥ 1.7 ] v low [ &lt; 1.7 ] ) , disease site ( esophageal v gastric/gastroesophageal junction ) . Patients randomize 1 2 treatment arm . - Arm I ( FOLFOX ) : Patients receive oxaliplatin IV 2 hour leucovorin calcium IV 2 hour day 1 , fluorouracil IV 46-48 hour day 1-2 . Courses repeat every 14 day absence disease progression unacceptable toxicity . - Arm II : Patients receive irinotecan hydrochloride IV 90 minute docetaxel IV 30-60 minute day 1 8 . Courses repeat every 21 day absence disease progression unacceptable toxicity . Blood tumor tissue sample may collect ERCC1 expression analysis future research study . After completion study treatment , patient follow every 3 month 3 year .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Stomach Neoplasms</mesh_term>
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Calcium , Dietary</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<mesh_term>Leucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Patients must unresectable advanced metastatic histologically cytologically confirm adenocarcinoma esophagus , stomach , gastroesophageal junction ( GEJ ) Patients must receive treatment metastatic unresectable disease Patients must brain metastasis Patients must measurable and/or nonmeasurable disease Patients HER2 expression test prior patient consent study must HER2 negative ; HER2 expression test prior patient consent study , second specimen must submit HER2 expression ; specimen HER2 positive ( HER2 could evaluate ) , patient randomized Patients must complete prior neoadjuvant adjuvant therapy resectable disease least 180 day prior registration PATIENT CHARACTERISTICS : Zubrod performance status 01 Hemoglobin ≥ 9 g/dL Absolute neutrophil count ( ANC ) ≥ 1,500/mcL Platelets ≥ 100,000/mcL Total bilirubin ≤ 1.5 mg/dL regardless whether patient liver involvement secondary tumor AST ALT ≤ 3 time institutional upper limit normal ( IULN ) unless liver involved tumor , case AST ALT must ≤ 5 time IULN Serum creatinine &lt; 1.5 mg/dL within 28 day prior registration AND/OR calculate creatinine clearance &gt; 60 mL/min Patients must motor sensory neuropathy &gt; Grade 1 use CTCAE version 4.0 Patients must pregnant nursing ; woman men reproductive potential must agree use effective contraceptive method No prior malignancy allow except follow : adequately treat basal cell squamous cell skin cancer , situ cervical cancer , adequately treated stage I II cancer patient currently complete remission , cancer patient diseasefree five year PRIOR CONCURRENT THERAPY : See Disease Characteristics All palliative radiation therapy alone must complete least 14 day prior registration Patient must plan receive concurrent chemotherapy , hormonal therapy , radiotherapy , immunotherapy , type therapy treatment cancer protocol treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>120 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>recurrent esophageal cancer</keyword>
	<keyword>stage IV esophageal cancer</keyword>
	<keyword>recurrent gastric cancer</keyword>
	<keyword>stage IV gastric cancer</keyword>
	<keyword>adenocarcinoma gastroesophageal junction</keyword>
	<keyword>stage IIIB gastric cancer</keyword>
	<keyword>stage IIIC gastric cancer</keyword>
	<keyword>stage IIIB esophageal cancer</keyword>
	<keyword>stage IIIC esophageal cancer</keyword>
	<keyword>adenocarcinoma esophagus</keyword>
	<keyword>adenocarcinoma stomach</keyword>
</DOC>